Publication: Pharmacogenetics of Warfarin Should we test?
2
Issued Date
2009
Resource Type
Language
eng
ISSN
0125-3611 (Print)
2651-0561 (Online)
2651-0561 (Online)
Rights
Mahidol University
Rights Holder(s)
Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
Bibliographic Citation
Ramathibodi Medical Journal. Vol. 32, No. 4 (Oct-Dec 2009), 157
Suggested Citation
Pantep Angchaisuksiri, พันธุ์เทพ อังชัยสุขศิริ Pharmacogenetics of Warfarin Should we test?. Ramathibodi Medical Journal. Vol. 32, No. 4 (Oct-Dec 2009), 157. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/79900
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacogenetics of Warfarin Should we test?
Author(s)
Other Contributor(s)
Abstract
Warfarin is the mainstay of anticoagulation therapy. It is used for the prevention and treatment of venous thromboembolism, myocardial infarction, and strokes. Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with associated adverse effects that are potentially serious, i.e., bleeding, and the dosage requirement to produce a required degree of anticoagulation varies widely between patients. The reason for the latter is multifactorial and includes determinants such as drugs, age, diet, race and genetic factors. To date, there has been no reliable means of predicting an individual’s response to warfarin prior to initiating therapy.
The discovery of common polymorphisms related to warfarin pharmacokinetics and pharmacodynamics over the last 10 years provides a unique opportunity to develop a pharmacogenetics-based approach to oral anticoagulant therapy. By using a pharmacogenetics-based approach to predict the patient’s maintenance dose a priori, initiation of warfarin therapy may become safer and more efficient.